Cardio Diagnostics (NASDAQ:CDIO) Stock Breaks Above Fifty Day Moving Average – What’s Next?

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.84 and traded as high as $1.90. Cardio Diagnostics shares last traded at $1.86, with a volume of 11,645 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Tuesday, September 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Cardio Diagnostics Trading Up 2.2%

The stock’s 50-day moving average price is $1.84 and its 200-day moving average price is $2.06. The company has a market cap of $5.51 million, a P/E ratio of -0.74 and a beta of 2.32.

Cardio Diagnostics (NASDAQ:CDIO) last issued its earnings results on Friday, November 6th. The company reported ($0.59) EPS for the quarter. Cardio Diagnostics had a negative net margin of 40,543.75% and a negative return on equity of 89.41%.

Institutional Trading of Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC purchased a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics as of its most recent filing with the SEC. 8.06% of the stock is owned by institutional investors.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc. is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care. The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.